NorthWest Biotherapeutics Inc (NWBO)

[Chiugray]

Yes information is available, just found this on overall survival data for IDH status for glioblastoma patients.

IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry, Dated 2015
https://www.oncotarget.com/article/5683/text/

274 IDH1/2 glioblastoma patients: mutation 56 patients, wildtype 209, NA 9

For the study population, the 6-month, 1-, 3-, and 5-year OS were 85, 65, 17 and 10%, respectively.

When both IDH mutation and MGMT promoter methylation status were considered, the patients exhibiting the longest OS and PFS were those with mIDH1 and methMGMT (35.8 and 27.5 mos, respectively).

Patients harboring either mIDH1 or methMGMT exhibited intermediate OS and PFS (14.1 and 9.4 mos, respectively).

Patients with wtIDH1 and unmethMGMT exhibited the worst PFS and OS (13.2 and 8.9 mos, respectively).